期刊
ENDOCRINE REVIEWS
卷 39, 期 5, 页码 629-663出版社
ENDOCRINE SOC
DOI: 10.1210/er.2017-00191
关键词
-
资金
- Dexcom
- Medtronic
- Bigfoot Biomedical
- Insulet
- Roche
- AstraZeneca
- Boehringer Ingelheim
- Gilead Sciences
- GlaxoSmithKline
- Hanmi Pharmaceutical
- Eli Lilly and Company
- ICON Clinical Research
- Janssen Pharmaceuticals
- Lexicon Pharmaceuticals
- Ligand Pharmaceuticals
- Merck Company
- Novo Nordisk
- Pfizer
- Sanofi-Aventis
- Takeda
- Eisai
- Amylin Pharmaceuticals
- BirdRock Bio
There has been an alarming increase in the prevalence of obesity in people with type 1 diabetes in recent years. Although obesity has long been recognized as a major risk factor for the development of type 2 diabetes and a catalyst for complications, much less is known about the role of obesity in the initiation and pathogenesis of type 1 diabetes. Emerging evidence suggests that obesity contributes to insulin resistance, dyslipidemia, and cardiometabolic complications in type 1 diabetes. Unique therapeutic strategies may be required to address these comorbidities within the context of intensive insulin therapy, which promotes weight gain. There is an urgent need for clinical guidelines for the prevention and management of obesity in type 1 diabetes. The development of these recommendations will require a transdisciplinary research strategy addressing metabolism, molecular mechanisms, lifestyle, neuropsychology, and novel therapeutics. In this review, the prevalence, clinical impact, energy balance physiology, and potential mechanisms of obesity in type 1 diabetes are described, with a special focus on the substantial gaps in knowledge in this field. Our goal is to provide a framework for the evidence base needed to develop type 1 diabetes-specific weight management recommendations that account for the competing outcomes of glycemic control and weight management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据